Related Experiment Video

Updated: Mar 23, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K

Sudden cardiac death markers in non-ischemic cardiomyopathy

Mauricio Pimentel1, Luis Eduardo Rohde2, André Zimerman3

  • 1Cardiac Electrophysiology Group, Hospital de Clinicas de Porto Alegre; Post-Graduate Program in Cardiology and Cardiovacular Sciences, Universidade Federal do Rio Grande do Sul.

Journal of Electrocardiology
|March 27, 2016
PubMed

Insights

Identifying patients with non-ischemic heart failure who are at high risk of sudden cardiac death is crucial. This helps ensure implantable cardioverter-defibrillator (ICD) therapy is cost-effective and benefits those most likely to need it.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Heart failure is a growing global health concern with significant morbidity and mortality.
  • Non-ischemic etiologies account for 30-40% of heart failure cases.
  • Implantable cardioverter-defibrillators (ICDs) reduce mortality in heart failure patients but carry costs and risks.

Purpose of the Study:

  • To review and discuss current risk stratification methods for sudden cardiac death (SCD) in patients with non-ischemic heart failure.
  • To identify patients who would most benefit from ICD implantation.
  • To guide cost-effective allocation of ICD therapy.

Main Methods:

  • Literature review of existing risk stratification tests for SCD in non-ischemic heart failure.
  • Analysis of the utility and cost-effectiveness of various diagnostic tools.
  • Discussion of clinical guidelines and expert consensus.

Main Results:

  • Current risk stratification tools for SCD in non-ischemic heart failure are varied.
  • No single test definitively identifies all patients who will benefit from ICDs.
  • Accurate risk assessment is essential for appropriate ICD implantation.

Conclusions:

  • Precise identification of high-risk patients is needed to optimize ICD use in non-ischemic heart failure.
  • Further research into improved risk stratification methods is warranted.
  • Targeted ICD implantation can improve outcomes and cost-effectiveness.

Keywords:
Non-Ischemic CardiomyopathyRisk stratificationSudden death

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.9K
A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

17.2K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
661
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
411
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
733
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.5K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
783